Cargando…
Evaluating Post-Market Adverse Events of The New Hepatitis C Therapies Using FEARS Data
Background: Little is known regarding the safety of direct-acting antivirals (DAA), even though they are widely used. This study aims to evaluate the adverse events of DAA using post-market data. Methods: FDA Adverse Events Reporting System (FAERS) data from January 2019 through December 2019 were a...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9408496/ https://www.ncbi.nlm.nih.gov/pubmed/36011057 http://dx.doi.org/10.3390/healthcare10081400 |